Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ?50%: 5-y Outcomes of EMPOWER-Lung 1

Basit Öğe Kaydı
dc.contributor.authorKılıçkap, S.
dc.contributor.authorSezer, A.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGümüş, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorGogishvili, M.
dc.contributor.authorNechaeva, M.
dc.date.accessioned2025-05-10T19:27:50Z
dc.date.issued2024
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[No abstract available]
dc.identifier.endpageS35
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue10
dc.identifier.scopusqualityQ1
dc.identifier.startpageS35
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7069
dc.identifier.volume19
dc.identifier.wosWOS:001337925600054
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofJournal of Thoracic Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleCemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ?50%: 5-y Outcomes of EMPOWER-Lung 1
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu